These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28150519)

  • 61. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study.
    Koziński M; Ostrowska M; Adamski P; Sikora J; Sikora A; Karczmarska-Wódzka A; Marszałł MP; Boinska J; Laskowska E; Obońska E; Fabiszak T; Kubica J
    Thromb Haemost; 2016 Nov; 116(6):1140-1149. PubMed ID: 27628615
    [TBL] [Abstract][Full Text] [Related]  

  • 63. COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
    Laine M; Gaubert M; Frère C; Peyrol M; Thuny F; Yvorra S; Chelini V; Bultez B; Luigi S; Mokrani Z; Bessereau J; Toesca R; Champenois A; Dignat-George F; Paganelli F; Bonello L
    Platelets; 2015; 26(6):570-2. PubMed ID: 25275609
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
    Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
    Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
    Teng R; Butler K
    Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Escalating Loading Dose Regimens of Ticagrelor in Primary Percutaneous Intervention: A Second Opportunity for IIb/IIIa Inhibitors?
    Lozano I; Rondan J; Vegas JM; Segovia E
    JACC Cardiovasc Interv; 2016 Mar; 9(6):623-4. PubMed ID: 27013165
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
    Teng R; Mitchell P; Butler K
    Eur J Clin Pharmacol; 2013 Apr; 69(4):877-83. PubMed ID: 23093043
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study.
    Kubica J; Adamski P; Buszko K; Kubica A; Kuliczkowski W; Fabiszak T; Jilma B; Alexopoulos D; Paciorek P; Navarese EP
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):152-157. PubMed ID: 29040445
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
    Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia.
    Moudgil R; Al-Turbak H; Osborne C; Hibbert B; So DY; Le May MR;
    Can J Cardiol; 2014 Nov; 30(11):1396-9. PubMed ID: 25442437
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.
    Asher E; Tal S; Mazin I; Abu-Much A; Sabbag A; Katz M; Regev E; Chernomordik F; Guetta V; Segev A; Elian D; Barbash I; Fefer P; Narodistky M; Beigel R; Matetzky S
    JAMA Cardiol; 2017 Dec; 2(12):1380-1384. PubMed ID: 29071332
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Periprocedural Myocardial Injury in High-Risk Patients With NSTEMI Pretreated With Ticagrelor for Less or More Than 6 Hours Before PCI.
    De Luca L; Pugliese M; Putini RL; Natale E; Piazza V; Biffani E; Petrolati S; Musumeci F; Gabrielli D
    J Clin Pharmacol; 2022 Jun; 62(6):770-776. PubMed ID: 34907543
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of Preloading Strategy With Ticagrelor on Periprocedural Myocardial Injury in Patients With Non-ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy.
    Karaca OF; Cimci M; Raimoglou D; Durmaz E; Yalman H; Tekin AM; Incesu G; Ozkan FU; Yavuz B; Karadag B
    J Cardiovasc Pharmacol; 2024 Apr; 83(4):311-316. PubMed ID: 38241694
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
    Åstrand M; Amilon C; Röshammar D; Himmelmann A; Angiolillo DJ; Storey RF; Gurbel PA; Bonaca MP; Hamrén B
    Br J Clin Pharmacol; 2019 Feb; 85(2):413-421. PubMed ID: 30414387
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
    Barbieri L; Verdoia M; Pergolini P; Nardin M; Rolla R; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):352-8. PubMed ID: 26857781
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
    Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial.
    Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Giorgio Masci P; Degrauwe S
    Circulation; 2020 Dec; 142(25):2479-2481. PubMed ID: 33347326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.